Share Price:

APNASPENAspen Pharmacare Hldgs21940-90 (-0.41%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Regional Overviews

Aspen in Asia

This region stands as the primary contributor to the Group’s Sterile Focus Brands revenue, encompassing all Asian territories, including China. The active trading subsidiaries are located in China, the Philippines, Taiwan, and Malaysia, while other territories in the region, like Hong Kong, are served through distributor partnerships. Furthermore, the region is home to a single manufacturing site located in Hyderabad, India, which specialises
in new product development.

Key Locations

India
Malaysia
Philippines
China Including Taiwan and Hong Kong (SAR)

Overview

Brand Therapeutic category

Arixtra

Antithrombotic agent

Diprivan

General anaesthetic

Fraxiparine

Low molecular weight heparin

Naropin

Regional anaesthetic

Ultiva

Injectable general anaesthetic

0
Products
Launched

(2022: 3)

Product
Recalls

(2022: Nil)

10 %
Average Staff
Turnover

(2022: 29%)

Work-related
Facilities

(2022: Nil)

410
Sales
Representatives

(2022: 535)

900
Permanent
Employees

(June 2022: 1,166)

Revenue 2023
R’million
2022 (CER)
R’million
Change
%

Total Commercial Pharmaceuticals

5 505

5 581

(1)

Regional Brands

737

677

9

Sterile Focus Brands

4 768

4 904

(3)

Manufacturing – FDF Other

115

130

(12)

Total

5 620

5 711

(2)

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.

Contribution to Group revenue (%)
Revenue by segment (%)

Source: China IMS CHPA Report, March 2023, IQVIA June 2023.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.